(JUNO) - Earnings & Price History

JUNO: - 48.6, $5.17B, 3.69 (8.22%)

Sector: Healthcare - Industry: Biotechnology

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The companys additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for t

Past JUNO reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-01AMC-0.6122.6225.3122.9521.8724.87-9.32%-1.44%-10.63%5.70M
2016-11-09AMC-0.5530.1428.4129.328.1330.53.13%▲2.87%6.09%2.89M
2016-08-04AMC-0.4131.4630.9230.6130.2832-1.00%2.78%1.75%2.08M
2016-05-09AMC-0.5238.4638.4936.7136.5339.24-4.62%4.77%-0.08%1.13M
2016-02-29-0.4739.9235.1734.2934.239.95-2.50%16.42%13.51%2.25M
2015-11-10AMC-0.4152.2851.8350.549.6652.89-2.57%▲3.52%0.87%908.39K

Login | Register
Monday Oct 15, 2018   EST
Enter a Ticker:

Economic Calendar

Retail Sales 8:30 AM ET Empire State Mfg Survey 8:30 AM ET Business Inventories 10:00 AM ET 4-Week Bill Announcement 11:00 AM ET 8-Week Bill Announcement 11:00 AM ET 3-Month Bill Auction 11:30 AM ET 6-Month Bill Auction 11:30 AM ET 

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades